Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug pralsetinib may change how the body processes other medications

NCT ID NCT07704658

Recruiting now Knowledge-focused Sponsor: Rigel Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib changes their levels in the blood. The goal is to understand potential drug interactions, helping doctors prescribe pralsetinib more safely alongside other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pralsetinib (Gavreto) and a cocktail of probe drugs (midazolam, repaglinide, losartan, estradiol/norethisterone acetate)
What this could lead to
If successful, this study could help doctors understand how pralsetinib interacts with other medications, leading to safer dosing guidelines for patients.
What could go wrong
This is a small, early-phase drug interaction study with only 12 participants, so results may not apply to all patients. The study does not test whether pralsetinib works against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm non-small cell lung carcinoma RET fusion positive cancer thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES NSCLC (NON-SMALL CELL LUNG CANCER) SOLID TUMOR MALIGNANCIES THYROID CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, 28050, Spain

    Contact Email: •••••@•••••

  • Hospital Universitario San Pedro

    RECRUITING

    Logroño, La Rioja, 26006, Spain

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.